Autoreactive B Cells in Membranous Nephropathy

Recruiting Observational Study
Membranous Nephropathy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
86 (estimated)
Sponsor
Mario Negri Institute for Pharmacological Research · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patients inclusion criteria * Males and females. * Adults (\> 18 years old). * Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practic…
Contacts

Manuel Podestà, MD

003903545351

manuel.podesta@guest.marionegri.it

CONTACT